Transplant Genomics Revenue and Competitors
Estimated Revenue & Valuation
- Transplant Genomics's estimated annual revenue is currently $24M per year.
- Transplant Genomics's estimated revenue per employee is $155,000
Employee Data
- Transplant Genomics has 155 Employees.
- Transplant Genomics grew their employee count by 25% last year.
Transplant Genomics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $7M | 45 | 73% | N/A | N/A |
#10 | $5.4M | 35 | 3% | N/A | N/A |
What Is Transplant Genomics?
Transplant Genomics is committed to improving organ transplant outcomes with noninvasive serial monitoring guided by genomics: TruGraf®. TruGraf is the only blood-based test covered by CMS to rule out "silent" subclinical rejection in stable kidney transplant recipients.
keywords:N/A
N/A
Total Funding
155
Number of Employees
$24M
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Transplant Genomics News
2022-04-20 - International Society for Heart and Lung Transplantation ...
... along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.
2022-03-22 - CareDx Partners with the European Society for Organ Transplantation to
Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European
Transplant Healthcare Professionals
ESOT attracts many of the top experts in global transplantation to work ... provider of genomics-based information for transplant patients.
Other Companies in Mansfield
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $50.4M | 158 | 5% | N/A |
#2 | $40.7M | 162 | -1% | N/A |
#3 | $38.8M | 168 | N/A | N/A |
#4 | $26.8M | 168 | -4% | N/A |
#5 | $67.9M | 187 | 27% | N/A |